Arrowhead Subsidiary Sees Phase I Data Publication as Key to Industry Partnership
February 18, 2010
Arrowhead Subsidiary Sees Phase I Data Publication as Key to Industry Partnership
Still, the company is uncertain when it will meet this goal and has put all partnership talks on hold, according to an official from Calando's parent firm Arrowhead Research.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Arrowhead Names HBV as Next RNAi Program While It Consolidates Operations
February 16, 2012 / Gene Silencing News - Arrowhead Reports Increased Fiscal Q4 Losses on Higher Expenses
December 22, 2011 / Gene Silencing News - Arrowhead to Move Calando Cancer Drug into Phase Ib, Reports Fiscal Q3 Results
August 11, 2011 / Gene Silencing News - Calando Aims to Complete RNAi Phase I Trial, Ink Development Partnership by Year's End
May 19, 2011 / Gene Silencing News - 'Not Happy' with Progress of Calando Phase I Solid Tumor Rx, Arrowhead Adding Third Clinical Site
February 17, 2011 / Gene Silencing News